• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matched unrelated allogeneic hematopoietic cell transplantation.

作者信息

Dachy François, Furst Sabine, Calmels Boris, Pagliardini Thomas, Harbi Samia, Bouchacourt Benjamin, Calleja Anne, Lemarie Claude, Collignon Aude, Morel Guillaume, Legrand Faezeh, Bekrieva Elena, Granata Angela, Weiller Pierre Jean, Chabannon Christian, Schiano Jean Marc, Vey Norbert, Blaise Didier, Devillier Raynier

机构信息

Department of Hematology, Institut Paoli-Calmettes, Marseille, France.

Cell Therapy Facility, Institut Paoli-Calmettes, Marseille, France.

出版信息

Bone Marrow Transplant. 2023 Nov;58(11):1179-1181. doi: 10.1038/s41409-023-02033-0. Epub 2023 Aug 9.

DOI:10.1038/s41409-023-02033-0
PMID:37558780
Abstract
摘要

相似文献

1
GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matched unrelated allogeneic hematopoietic cell transplantation.在10/10 HLA匹配的无关供者异基因造血细胞移植中，与抗胸腺细胞球蛋白相比，移植后环磷酰胺预防移植物抗宿主病（GVHD）可降低GVHD的发生率，并允许更快地减少免疫抑制治疗。
Bone Marrow Transplant. 2023 Nov;58(11):1179-1181. doi: 10.1038/s41409-023-02033-0. Epub 2023 Aug 9.
2
Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors.在接受 10/10 HLA 匹配的无关供体异基因干细胞移植的处于首次完全缓解的急性髓系白血病患者中，移植后环磷酰胺与抗胸腺细胞球蛋白的比较。
J Hematol Oncol. 2020 Jul 3;13(1):87. doi: 10.1186/s13045-020-00923-0.
3
Outcomes of Antithymocyte Globulin-Post-Transplantation Cyclophosphamide-Cyclosporine-Based versus Antithymocyte Globulin-Based Prophylaxis for 10/10 HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation.抗胸腺细胞球蛋白移植后环磷酰胺-环孢素与抗胸腺细胞球蛋白预防 10/10 HLA 匹配非亲缘供体异基因造血细胞移植的结果。
Transplant Cell Ther. 2024 May;30(5):536.e1-536.e13. doi: 10.1016/j.jtct.2024.01.075. Epub 2024 Jan 27.
4
First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia.与一线使用环孢素和/或抗胸腺细胞或抗淋巴细胞球蛋白治疗获得性重型再生障碍性贫血相比，HLA匹配的同胞供者进行一线异基因造血干细胞移植的情况。
Cochrane Database Syst Rev. 2013 Jul 23;2013(7):CD006407. doi: 10.1002/14651858.CD006407.pub2.
5
Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.使用白消安、氟达拉滨和抗胸腺细胞球蛋白进行减低强度预处理用于缓解期急性髓系白血病患者接受无关或单倍体相合家庭供者造血细胞移植
Biol Blood Marrow Transplant. 2017 Sep;23(9):1555-1566. doi: 10.1016/j.bbmt.2017.05.025. Epub 2017 May 25.
6
Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.低剂量抗胸腺细胞球蛋白在成人获得性重型再生障碍性贫血无关供者干细胞移植中的有益作用：降低移植物抗宿主病并提高无移植物抗宿主病、无失败生存率
Biol Blood Marrow Transplant. 2017 Sep;23(9):1498-1508. doi: 10.1016/j.bbmt.2017.05.026. Epub 2017 May 26.
7
Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies.降低强度预处理方案联合抗胸腺细胞球蛋白和移植后环磷酰胺预防移植物抗宿主病在血缘单倍体造血干细胞移植治疗血液系统恶性肿瘤中的应用。
Biol Blood Marrow Transplant. 2018 Nov;24(11):2259-2264. doi: 10.1016/j.bbmt.2018.07.008. Epub 2018 Aug 7.
8
Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.异基因造血细胞移植治疗匹配无关供体来源的急性淋巴细胞白血病患者中：环磷酰胺与抗胸腺细胞球蛋白的比较：来自欧洲血液和骨髓移植学会急性白血病工作组的研究。
Cancer. 2023 Dec 1;129(23):3735-3745. doi: 10.1002/cncr.35004. Epub 2023 Sep 1.
9
Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.与抗胸腺细胞球蛋白、钙调神经磷酸酶抑制剂和甲氨蝶呤联合用药相比，移植后环磷酰胺、钙调神经磷酸酶抑制剂和霉酚酸酯用于急性髓系白血病患者同胞及非血缘供者异基因干细胞移植后移植物抗宿主病的预防：代表欧洲血液与骨髓移植学会急性白血病工作组的一项研究
Bone Marrow Transplant. 2024 Jul;59(7):1012-1021. doi: 10.1038/s41409-024-02284-5. Epub 2024 Apr 13.
10
Post-transplantation cyclophosphamide as GVHD prophylaxis in allogenic hematopoietic stem cell transplantation: Recent advances and modification.移植后环磷酰胺作为异基因造血干细胞移植中的移植物抗宿主病预防：最新进展和改良。
Blood Rev. 2023 Nov;62:101078. doi: 10.1016/j.blre.2023.101078. Epub 2023 Mar 30.

本文引用的文献

1
Post-transplant cyclophosphamide versus antithymocyte globulin in allogeneic hematopoietic cell transplantation: a meta-analysis.移植后环磷酰胺与抗胸腺细胞球蛋白在异基因造血细胞移植中的比较：一项荟萃分析。
Ann Hematol. 2021 Feb;100(2):529-540. doi: 10.1007/s00277-021-04399-x. Epub 2021 Jan 8.
2
Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors.在接受 10/10 HLA 匹配的无关供体异基因干细胞移植的处于首次完全缓解的急性髓系白血病患者中，移植后环磷酰胺与抗胸腺细胞球蛋白的比较。
J Hematol Oncol. 2020 Jul 3;13(1):87. doi: 10.1186/s13045-020-00923-0.
3
Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
在接受无关供体移植的血液系统恶性肿瘤患者中，在标准移植物抗宿主病预防方案基础上加用抗胸腺细胞球蛋白与单纯标准治疗的对比：一项随机、开放标签、多中心3期试验的最终分析。
Lancet Haematol. 2020 Feb;7(2):e100-e111. doi: 10.1016/S2352-3026(19)30220-0. Epub 2020 Jan 17.
4
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).三种预防方案（他克莫司、霉酚酸酯和环磷酰胺；他克莫司、甲氨蝶呤和硼替佐米；或他克莫司、甲氨蝶呤和马拉维若）与他克莫司和甲氨蝶呤用于预防低强度预处理造血细胞移植后的移植物抗宿主病：一项带有非随机同期对照组的随机2期试验（BMT CTN 1203）
Lancet Haematol. 2019 Mar;6(3):e132-e143. doi: 10.1016/S2352-3026(18)30221-7.
5
PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.基于 PTCy 的单倍体相合与匹配相关或无关供者减低强度预处理移植治疗弥漫性大 B 细胞淋巴瘤。
Blood Adv. 2019 Feb 12;3(3):360-369. doi: 10.1182/bloodadvances.2018027748.
6
Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.使用单倍体相合相关供者与 HLA 配型相合无关供者进行淋巴瘤的减低剂量预处理移植。
Blood. 2016 Feb 18;127(7):938-47. doi: 10.1182/blood-2015-09-671834. Epub 2015 Dec 15.
7
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.在来自匹配无关供者的造血细胞移植中使用或不使用抗T细胞球蛋白进行标准移植物抗宿主病预防：一项随机、开放标签、多中心3期试验。
Lancet Oncol. 2009 Sep;10(9):855-64. doi: 10.1016/S1470-2045(09)70225-6. Epub 2009 Aug 18.